Comparative Pharmacology
Head-to-head clinical analysis: CEFADYL versus CEFOTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFADYL versus CEFOTAN.
CEFADYL vs CEFOTAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activation.
Cefotetan is a cephamycin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking, and activating autolytic enzymes.
1-2 g IV/IM every 6 hours for moderate to severe infections; maximum 12 g/day.
1-2 g IV/IM every 12 hours for 5-10 days; up to 6 g/day for severe infections.
None Documented
None Documented
30-60 minutes in adults with normal renal function; prolonged to 10-20 hours in end-stage renal disease. Requires dose adjustment for CrCl <30 mL/min.
Terminal elimination half-life: 4.5 hours (intravenous). In patients with renal impairment (CrCl <30 mL/min), half-life extends to approximately 20–30 hours, requiring dose adjustment.
Renal: 90-95% unchanged via glomerular filtration and tubular secretion. Biliary: <1%. Fecal: minimal.
Primarily renal (unchanged); ~88% excreted in urine within 24 hours. Biliary/fecal elimination is negligible (<1% as metabolites).
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic